Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia
Hans Rydholm, Ann Aurell-Holmberg(AstraZeneca (Sweden)), Hans Denison(Université Sorbonne Paris Nord), Jörgen Jensen, Magnus Ruth(AstraZeneca (Sweden)), Christian von Corswant(AstraZeneca (Sweden)), Anders Lehmann(AstraZeneca (United Kingdom)), Erik Söderlind(AstraZeneca (Sweden))
Cited by 3
Related Papers
Ischemia-Induced Shift of Inhibitory and Excitatory Amino Acids from Intra- to Extracellular Compartments
|Journal of Cerebral Blood Flow & Metabolism|1985|660
Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in normal subjects
|Gastroenterology|2000|326
Effects of <i>In Vivo</i> Administration of Kainic Acid on the Extracellular Amino Acid Pool in the Rabbit Hippocampus
|Journal of Neurochemistry|1983|214
The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection
|Neuroscience Letters|1988|176
Activation of the GABAB receptor inhibits transient lower esophageal sphincter relaxations in dogs
|Gastroenterology|1999|153